Steven Chapman is the Chief Executive Officer and President of Natera, Inc., a leading diagnostics company focused on developing and commercializing non-invasive genetic tests. With a strong background in healthcare and biotechnology, Chapman has been instrumental in guiding Natera's growth and success since joining the company in 2007. Prior to his appointment as CEO in 2009, he served as the company's Chief Operating Officer, overseeing the development and launch of Natera's flagship product, the Panorama non-invasive prenatal test. Under Chapman's leadership, Natera has expanded its product portfolio to include innovative tests for oncology, organ health, and women's health. His strategic vision and commitment to scientific excellence have positioned Natera as a pioneer in the field of cell-free DNA testing. Chapman has successfully led the company through multiple rounds of funding, including a successful IPO in 2015, and has fostered key partnerships with leading academic institutions and healthcare providers. His focus on delivering high-quality, clinically validated tests has earned Natera a reputation for innovation and reliability in the diagnostics industry. As CEO and President, Steven Chapman continues to drive Natera's mission to transform the way genetic information is used to improve patient care. His leadership style emphasizes collaboration, innovation, and a patient-centric approach to healthcare. Chapman's dedication to advancing the field of personalized medicine has not only propelled Natera's growth but has also contributed to the broader adoption of non-invasive genetic testing in clinical practice. With his extensive experience and unwavering commitment to improving patient outcomes, Steven Chapman remains a respected leader in the biotechnology and diagnostics sectors.